Artelo Biosciences Inc

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded by James Manley on May 2, 2011 and is headquartered in Solana Beach, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

The stock price of Artelo Biosciences Inc (NASDAQ: ARTL) increased by over 60% pre-market today. This is why it happened.

ARTL Stock: Why The Price Surged Today

Artelo Biosciences, Inc. (ARTL) Q3 2021 Results - Earnings Call Transcript

Solana Beach, California--(Newsfile Corp. - August 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that management will present at the Q3 Virtual Investor Summit, hosted by the Investor Summit Group, being held virtually on August 17-18, 2021.Andrew Yates, PhD, Senior Vice President and Chief Scientific Officer is scheduled to present as follows. Randy...

Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th

Study finds no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD

Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines

LA JOLLA, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that Ladenburg Thalmann & Co. Inc. will host an R&D showcase focused on the Phase 1b/2a Cancer Appetite Recovery Study (“CAReS”), evaluating the Company's lead drug candidate, ART27.13. The webinar will be hosted by Michael Higgins, Managing Director and Senior Biopharmaceutical Equity Research Analyst on July 28th, 2021 at 1pm EDT/10am PDT. This event will include the lead investigator on the CAReS study, Barry Laird, PhD, a Senior Clinical Consultant of Palliative Medicine at St Columba's Hospice Care in Edinburg, UK. Among a number of key topics, Dr. Laird will be discussing the etiology of anorexia and the accompanying challenges of effectively treating anorexia.

Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences' CAReS Study on July 28, 2021

Enrollment in CAReS Study in patients with cancer anorexia on track to deliver first data readout by calendar year-end

Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update

Exciting opportunities are emerging for new therapies that target the recently identified endocannabinoid system, which governs numerous cellular processes in human body. To economically build portfolio value, Artelo's business model relies on both in-licensed and internally developed compounds and contracts for clinical services.

Relief For Cancer Patients In Artelo Bioscience Pipeline

Dr. Andrew Yates to Present Poster on the Company's ART27.13 Cancer Appetite Recovery Study

Artelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium

LA JOLLA, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021.

Artelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th

Recently Commenced Patient Enrollment in Phase 1/2 CAReS Study of ART27.13 in the UK

Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update

Initial safety data expected from CAReS Study before end of 2021

Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

Artelo Biosciences, Inc. (ARTL) CEO Gregory Gorgas Presents at Q1 Virtual Investor Summit Conference (Transcript)

Detection of elevated FABP5 associated with additional tumor types suggests  the target for ART26.12 may be more broadly relevant in cancer therapy

Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development

LA JOLLA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo Biosciences, will be presenting at the Q1 Virtual Investor Summit.

Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd

The stock price of Artelo Biosciences Inc (NASDAQ: ARTL) has increased by over 30% pre-market. This is why it happened.

ARTL Stock Price Increases Over 30% Pre-Market: Why It Happened

LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company's board of directors.

Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors

LA JOLLA, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, Chief Executive Officer of Artelo Biosciences, will be presenting at the H.C. Wainwright Life Sciences Conference to be held virtually between March 9-10, 2021.

Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th

Research demonstrates co-administration of CBD and TMP could confer ART12.11 with a more desirable pharmacodynamic profile Research demonstrates co-administration of CBD and TMP could confer ART12.11 with a more desirable pharmacodynamic profile

Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal

Artelo Biosciences (ARTL) stock is soaring higher on Friday after Ladenburg analyst Michael Higgins initiated coverage of the company. The post ARTL Stock Alert: The Big Reason Biopharma Artelo Biosciences Is Rocketing Today appeared first on InvestorPlace.

ARTL Stock Alert: The Big Reason Biopharma Artelo Biosciences Is Rocketing Today

The stock price of Artelo Biosciences Inc (NASDAQ: ARTL) is trading at over 60% pre-market today. This is why it happened.

ARTL Stock Price Increases Over 60% Pre-Market: Why It Happened

LA JOLLA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the exercise of a portion of the warrants from its October 2020 financing. Existing investors agreed to exercise warrants for net proceeds of approximately $3 million.

Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants

LA JOLLA, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (NASDAQ:  ARTL ) today embarks on a collaboration with researchers from Trinity College Dublin to investigate pre-clinical models of human cancer cachexia, a wasting syndrome that affects up to 80% of all cancer patients and is believed to hasten death in this population.

Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia

The stock price of Artelo Biosciences Inc (NASDAQ: ARTL) has increased by over 97% pre-market. This is why it happened.

ARTL Stock Price Increases Over 97% Pre-Market: Why It Happened

LA JOLLA, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be presenting at the LSX World Congress to be held virtually between February 1-5, 2021.

Artelo Biosciences to Present at the LSX World Congress Virtual Conference

Received Clinical Trial Authorization to Commence Cancer Appetite Recovery Phase I/II Clinical Study of ART27.13 in UK

News for Artelo Biosciences Inc Stock (ARTL)